




Contact Us

Media Inquiries: PR@wuxibiologics.com
Business Inquiries: info@wuxibiologics.com
ESG Inquiries: ESG@wuxibiologics.com
Investor Inquiries: IR@wuxibiologics.com

As of December 31st, 2023 wuxibiologics.com



Benefiting Patients Worldwide

Every drug can be made and every disease can be treated

WuXi Biologics Global Premier CRDMO – Enabling Partners to Expedite Innovations

Vision

"Every drug can be made and every disease can be treated" by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry.

Mission

To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide.

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable our partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Next-generation biomanufacturing technologies and clean-energy sources are used in our facilities.











How to transform an idea into a breakthrough therapy?



Enable organizations to discover, develop and manufacture biologics

WuXi Biologics' unique CMC matrix management concept and model – supported by our efficient execution – ensures seamless and flexible cooperation between our technical team and global partners, and helps guarantee round-the-clock service to clients throughout the world.

We continue to increase our capacity to meet growing client demand worldwide, demonstrating great synergy within our existing network and a strong commitment to our "Global Dual Sourcing" strategy. Our global manufacturing network ensure that products can be manufactured and materials can be sourced at multiple WuXi Biologics facilities around the world.



Strategy

Robust global network supports "Follow and Win the Molecule" strategy



capacity has become increasingly prominent in the global biologics market. One of the principal challenges is achieving high output, high quality and high flexibility while keeping costs controlled.

The discrepancy between growing manufacturing demand and limited

Reflecting the strength of our "Follow and Win the Molecule" business strategy, we enabled hundreds of projects in both clinical phases and commercial manufacturing phase for biologics used in the treatment of cancer, autoimmune and central nervous system disorders, infections, rare disease and other diseases.

Expanding capacity allows any project to start within 4 weeks

We employ a Global Dual Sourcing manufacturing strategy through our facilities in the United States, Ireland, Germany, Singapore and China. To effectively meet the rapidly growing needs of our partners, WuXi Biologics is expanding its biomanufacturing capacity to ensure a robust global supply chain that provides biologics of premier quality.

- **≥** 3 Research Centers (R)
- 8 Development Centers (D)
- 9 Manufacturing Centers (M)



Massachusetts

Pennsylvania

New Jersey





.........



120,000L

Singapore

















Dundalk, Ireland

Partial Site Photos

Visit wuxibiologics.com for more site photos

Leverkusen, Germany

Wuppertal, Germany

New Jersey, U.S.

Massachusetts, U.S.

Boston, U.S.

Tuas, Singapore

Wuxi, China

Shanghai, China

Suzhou, China

Hangzhou, China


Hebei, China

Chengdu, China

Flexibility

End-to-end solutions for global partners

WuXi Biologics Value Chain



Mammalian Fc-fusion Viral Virus Like Recombinant Plasmid mRNA Monoclonal Bispecific Antibody Drug Oncolytic Antibody Vaccine Particle (VLP) DNA Antibody Protein Conjugate Virus Antibody Fragments Protein Microbial

WuXi Biologics' end-to-end services, advanced technologies, quality systems and manufacturing success rates put us at the leading edge of the CRDMO industry. We continually enhance our services and improve the management of our supply chains so we can offer our clients the most comprehensive capabilities in the global biopharmaceutical industry.

Always customer first, WuXi Biologics provides integrated services - from new drug discovery to biologics manufacturing, as well as customized services for drug development and CMC - with flexibility and execution excellence that is widely recognized and trusted by our clients.

8

Technology

New technology platforms accelerate biologics innovation



Enabling innovation is one of the key driving forces of WuXi Biologics' growth. We aim to establish a comprehensive platform, with leading technologies that allow our global partners to accelerate biologics innovation, benefiting more patients worldwide.

We have developed technology platforms that cover the entire biologics development process – from concept to commercial manufacturing – improving efficiency and lowering costs for our clients.



Proprietary Universal Bispecific Antibody Platform



Bispecific & Multispecific Antibody Platform



Display Library



Proprietary High Titer Production CHO K1 Cell Line Development Platform



Ultra-High Productivity Continuous Bioprocessing Platform



Rapid, High-Quality Protein Production Platform




Comprehensive ADCs Development Platform



Ultra-Intensified Fed-Batch Platform



High Concentration and High-Throughput
DP Development







Biotech



Pharma



Academia

In April 2021, one of our global partners announced that its PD–1 antibody – a treatment for women with endometrial cancer – had been conditionally approved by the U.S. FDA and the EMA. This project marked several "firsts" for WuXi Biologics:

- The first time we were involved in the entire process of research and development for a product from DNA to BLA approval.
- The first time single-use bioreactor manufacturing technology was applied to large-scale biomanufacturing through a scale-out production strategy.
- The first project to successfully pass the U.S. FDA's remote audit.

The success of this project is a testament to the extensive technical capabilities of WuXi Biologics talent, and our commitment to excellence and quality.

Our WuXiUP™ platform, which is based on perfusion cell culture, can increase the accumulated product yield for almost any type of biological drug by five to ten times compared with fed–batch cultivation. The continuous-harvest model greatly shortens the time that protein products spend in the reactor, creating higher quality products and making downstream purification more efficient.

Thus far, the WuXiUP™ platform has been applied successfully to over 40 biologics manufacturing projects – including mAbs, bispecific antibodies, fusion proteins, and other recombinant proteins – with scales varying from 3 liters to 1000 liters.

As part of its drive to foster innovation, WuXi Biologics launched a new advanced technology platform during the Reporting Period – WuXiUITM, a novel proprietary bioprocessing platform that significantly boosts productivity and quality for various cell lines and product modalities. This ultra-intensified fed-batch solution aims to revolutionize upstream processing by enhancing productivity by 3-6 times and reducing manufacturing costs substantially compared to traditional processes. WuXiUITM offers exceptional flexibility and competitiveness in meeting different commercial market supply and manufacturing needs.

Our proprietary bispecific antibody platform, WuXiBody™, known for its flexibility and capability to combine almost any mAb pair, continued to earn global recognition, with rights of 45 projects granted to external partners.

 $\mathbf{9}$

People

Enhancing Diversity, Equity and Inclusion (DEI) awareness

Our senior scientists team have advanced degrees with rich industry work experience in antibody development, manufacturing, quality control, preclinical research and registration. Our senior management members have worked at the forefront of the biologics industry over the last 20 years, enabling us to create a world-class biologics discovery, development and manufacturing team.

WuXi Biologics believes in building inclusive working environments where everybody has the opportunity to thrive. We set targets for achieving balanced overall gender representation and for having 45% female employees in managerial positions across our global organizations. To reach these goals, multiple initiatives have been rolled out, including Women Leadership Forums and a global WiSTEM program.

4,400+ one of the largest biologics development teams in the world




800+ Ph.D. or equivalent

96.8%+

key talent retention

female employees



STEM positions taken by female employees





Practicing corporate social responsibility and encouraging employee volunteerism

Generating social value is central to our sustainability strategy. We are dedicated to operating in a socially responsible manner and helping to improve the health of local communities. Our employees are encouraged to volunteer and demonstrate their social and environmental commitment.



Paintings by children diagnosed with rare disease

Public health is integral to the work we do at WuXi Biologics. We leverage our strengths to benefit patients worldwide, especially in the area of rare disease, supporting the R&D of pioneers specializing in rare disease drugs, and helping to advance better care for these patients. As of December 31, 2023, there are 19 ongoing rare disease projects on our platform.

We have been providing scholarships to students with rare diseases for over three years through educational support programs for high school and college students suffered from these diseases. So far, we've granted scholarships and educational packages to 62 students.

In December, 2023, a magnitude earthquake struck Jishishan and several counties in Gansu and Qinghai Province. We quickly coordinated various of relief materials, which were dispatched to the afflicted area of the disaster at speed. In total, the donation value exceeds RMB 1 million, including materials and cash donation.

To foster a sense of shared community, we organized a series of activities through the company-wide volunteer association. Employee volunteers take advantage of their expertise and spontaneously take part in community activities, and become the company's important force in fulfilling social responsibilities.

8,017 volunteer hours



1,907 person-times of



Quality

Committed to the highest quality standards



WuXi Biologics remains dedicated to meeting the highest industry quality standards. With its world-class quality system, we have completed 33 regulatory inspections conducted by the U.S. FDA, EU EMA, China NMPA, and other global regulatory agencies since 2017 with no critical issues identified and zero data integrity findings.

WuXi Biologics has completed more than 1,200 GMP audits by global clients, and more than 120 audits by EU Qualified Persons. These audits and certifications demonstrate to clients that the companies' quality system adheres to global standards, ensuring the provision of the highest quality biologics to patients worldwide.





























I have worked with 12 CMOs over the past 6 years. WuXi Biologics' quality standard and adherence to the schedule are truly outstanding. Their team is very flexible and goes the extra mile to meet schedule requirements.



Far beyond our expectations. We expect to pay for services, but were surprised at the level of commitment and collaboration that was included – hard to achieve in a tough year. 🤧



The best team that I have ever worked within my 40-year career. It is very special and rare in the industry to have so many projects going on at the same time but WuXi Biologics makes it.



Someone asked me my thoughts of WuXi Biologics. I said it's very difficult for other companies to compete with the one that says yes all the time. 🤧

Speed

Making the impossible possible at WuXi Biologics Speed

WuXi Biologics has continually invested in the innovation, research, and development of new-generation continuous manufacturing technology platform that connects upstream and downstream processes to enable high-quality, large-scale, low-cost, and flexible biomanufacturing. WuXi Biologics Speed and WuXi Biologics Quality ensure that projects are delivered on time and meet client expectations.



3.5 months

WuXi Biologics supported Brii Bioscience (Brii Bio) to develop the COVID-19 neutralizing mAbs ambavir and romizumab - efficiently completing all required CMC studies and the IND filings in just three and an half months.

month

WuXi Biologics completed in seven months all the IND - enabling CMC studies for TY014, a first-in-class monoclonal antibody candidate for vellow fever.

9 mont

The Investigational New Drug (IND) package for Tyzivumab - a client's monoclonal antibody designed and engineered to treat Zika-infected patients that was first-in-class to enter the clinic - was developed by WuXi Biologics in a record time of 9 months.

10-12_{months}

WuXi Biologics shortened the timeline from DNAs to INDs to 10-12 months, compared with the standard timeline of 18-24 months.

14 months

WuXi Biologics partnered with a bio pharma to enable the development of a COVID-19 neutralizing mAb, which was awarded Emergency Use Authorization by the FDA within 14 months.



16

Execution

Advancing public health efforts



Pharmaceutical companies around the world responded quickly to the outbreak of COVID-19 and have initiated multiple vaccines and biologics projects. As a trusted partner, we have made – and continue to make – contributions to those global efforts with our professional and dedicated team, leading technologies, shortened timelines, and excellent execution, as well as rich experience in the field of infectious diseases. We enable our partners to accelerate the research, development and manufacturing of innovative neutralizing antibodies and vaccines.

The mission that unites us all

Support 40+ IND filings for COVID-19 projects globally

6 g/L average titer for COVID-19 mAbs



neutralizing antiboo

Billionsof doses of COVID-19
vaccine delivered



14 months from DNA to EUA



2.5 months from DNA to IND, one of the industry's fastest programs (conventional timing is 18–24 months)





WuXi Biologics' nimble response to the pandemic was founded on the robust risk management and control protocols we have built over time. Our business continuity management (BCM) system safeguards against disruption by identifying risks that impact our operations, while providing a targeted emergency response plan to mitigate those disruptions. Accordingly, at the outset of the pandemic, we were able to resume normal operations promptly, while ensuring the health and safety of our staff.

17

Sustainability Commitment Environmental, Social and Governance



ESG Ratings

Named to 2023 Dow Jones Sustainability™ Sustainability Indices World Index and Emerging Markets Index, identified as an industry mover and included into Sustainability Yearbook



Received an AAA rating from MSCI



Awarded a distinguished Platinum Medal by EcoVadis in recognition of its sustainability achievements





Recognized as both an Industry Top-Rated and APAC Regional Top-Rated Company by Sustainalytics



Named to CDP Water Security "A list"; Received a CDP Climate Change "A-" Leadership-level score

ESG Commitments



A participant of the United Nations Global Compact, demonstrating commitment to robust sustainability



Committed to Science Based Targets Initiative (SBTi), a new milestone towards



ISO 27001

ISO 14064

ISO 45001 ISO 14001 Environmental Management ISO 50001

Information Security Management Occupational Health and Safety Management

Energy Management GHG Emissions Verification

Environmental, Social and Governance

9

ESG Committee

Comprised of four board members led by CEO

Material ESG issues

100%

Participation in business ethics and anti-corruption training

100%

Supplier Code of Conduct sign off

ISO 27001

Information security management certification

Integrated projects

Inspections by global regulatory agencies were passed

-,200+

Client quality audits were passed

Rare disease projects on the platform

8,017

Volunteer hours

Female employees in managerial positions

53%

STEM positions held by female employees

Natonalities of our global employees

73 hours

of training per employee

ISO 45001

Occupational health & safety management certification

29%

Reduction of GHG emission intensity from 2020 (Scope 1 and Scope 2)

Upgraded Water Target

30% reduction of water consumption intensity by 2025 from 2019

ISO 14064

GHG emissions verification

ISO 14001

Environmental management certification

ISO 50001

Energy management certification


Dundalk, Ireland





100% renewable electricity supply





Solar power usage to help achieve carbon



Hydro-treated Vegetable Oil instead of diesel to reduce reliance on fossil fuels



EV chargers in car park to promote sustainable transportation among employees

Hebei, China





Green and low-carbon approach – from design to operation







Cutting-edge technologies include continuous manufacturing process and environmental friendly single-use bioreactors



Water recycling and heat recovery minimize water and energy consumption, and rainwater harvesting saves over 1,000 tonnes of water annually

Global Sites





Solar power at global sites provides renewable electricity for daily operations


Global partners continue to expand

Continuously improving customers' satisfaction wins their trust

Trusted by 600+ partners worldwide, including ALL of the TOP 20 pharmaceutical companies



Widely recognized by multiple organizations in terms of industry leadership, capital performance, employer brand and ESG



Milestones

2017

WuXi Biologics is officially listed on the Hong Kong Stock Exchange.

WuXi Biologics completes PLI of its cGMP manufacturing facilities by the U.S. FDA.

2018

WuXi Biologics begins global footprint (Ireland, Singapore, U.S.).

2019

WuXi Vaccines announces plans to build a manufacturing facility in Ireland.

WuXi Biologics signs Letter of Intent for long-term vaccine manufacturing contract with a global vaccine leader.

2019

WuXi Biologics receives EMA GMP certificates for its cGMP Drug Substance and Drug Product manufacturing facilities in Wuxi city and its cGMP cell banking facilities in Shanghai.

WuXi Biologics launches GMP production at an ADC facility for Drug Substance and Drug Product manufacturing.

2022

WuXi Biologics launches first commercial drug product facility for pre-filled syringes.

WuXi Biologics announces USD\$1.4 billion (S\$2 billion) investment plan to establish a fully integrated CRDMO center in Singapore.

WuXi Biologics announces GMP release of its first North American biomanufacturing facility in Cranbury, New Jersey.

WuXi Biologics announces GMP release of 48,000L commercial drug substance manufacturing facility in Hebei, China.

WuXi Biologics launches an Integrated Biologics CRDMO Center in Fengxian, Shanghai.

2021

WuXi Biologics celebrates 10th Anniversary.

WuXi Biologics announces plans to acquire Drug Substance and Drug Product facilities from Pfizer China, and to acquire CMAB Biopharma Group.

WuXi Biologics receives a commercial manufacturing license from the German health authorities for its drug product facility in Leverkusen, Germany.

2021

WuXi Biologics launches GMP operation in Wuxi city with the world's largest 60,000L biomanufacturing line using single-use bioreactors.

WuXi XDC was established to provide fully integrated bioconjugates CDMO services.

2020

WuXi Biologics enters into an acquisition agreement with Bayer for a Drug Product plant in Germany.

WuXi Biologics (Suzhou) receives EMA GMP certificate for biosafety testing.

WuXi Biologics launches Biologics Integrated Innovation Center in Hangzhou.

2023

WuXi Biologics increases manufacturing in Germany, with MFG19 being expanded to 24,000L and DP7 being expanded to include a second variable filling line.

WuXi Biologics commits to Science Based Targets Initiative.

WuXi Biologics receives a 2023 Facility of the Year Award FOYA by International Society for Pharmaceutical Engineering ISPE.

WuXi XDC is listed on the main board of HKEX.

2024

WuXi Biologics increases the total manufacturing capacity of its facility in Worcester, Massachusetts to 36,000L.

WuXi Biologics breaks ground on CRDMO center in Singapore.

WuXi Biologics successfully completes first 16,000L manufacturing run in Ireland.

WuXi Biologics
Global Solution Provider